Elite in Cholangiocarcinoma (Bile Duct Cancer)

Shoji Kubo

Health Education Course, 
Shitennoji, JP 
Elite in Cholangiocarcinoma (Bile Duct Cancer)
Health Education Course, 
Shitennoji, JP 
OverviewLocationsClinical Research

Overview

Shoji Kubo practices in Shitennoji, Japan. Mr. Kubo is rated as an Elite expert by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). His top areas of expertise are Cholangiocarcinoma (Bile Duct Cancer), Liver Cancer, Hepatitis, Hepatectomy, and Hepato-Pancreato-Biliary Surgery.

His clinical research consists of co-authoring 243 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 65 articles and participated in 1 clinical trial in the study of Cholangiocarcinoma (Bile Duct Cancer).

Gender
Male

Locations

Health Education Course, Shitennoji, 5838501, Japan
Other Locations
Health Education Course, 3-2-1 Gakuenmae, Habikino, 5838501, Japan
Osaka, Japan
Yokohama, Japan
Asahimachi, 5450051, Japan
Hori, 5458585, Japan
Tokyo, Japan
Japan
Sayama, Japan
Nishinomiya-hama, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) as First-line Treatment of Biliary Tract Cancer
A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) as First-line Treatment of Biliary Tract Cancer
Enrollment Status: Terminated
Publish Date: November 14, 2023
Intervention Type: Drug
Study Drugs: Bintrafusp Alfa, Gemcitabine, Cisplatin
Study Phase: Phase 2/Phase 3

243 Total Publications

Subclassification-Specific Tumor Immune Microenvironment in Intrahepatic Cholangiocarcinoma: Implications for Appropriate Pharmacotherapy.
Subclassification-Specific Tumor Immune Microenvironment in Intrahepatic Cholangiocarcinoma: Implications for Appropriate Pharmacotherapy.
Journal: Cancers
Published: May 20, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Kubo's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 35 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile